



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burrows et al.

Art Unit: 1644

Application No. 09/847,172

CERTIFICATE OF EXPRESS MAILING

Filed: May 1, 2001

For: RECOMBINANT MHC MOLECULES USEFUL  
FOR MANIPULATION OF ANTIGEN-  
SPECIFIC T-CELLS

Examiner: To be assigned

Date: December 5, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on December 5, 2001 as Express Mail, Label No. EL761161399US, in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 2327, ARLINGTON, VIRGINIA, 22202.

  
Susan Alpert Siegel, Ph.D.  
Agent for ApplicantTRANSMITTAL LETTERCOMMISSIONER FOR PATENTS  
P.O. BOX 2327  
ARLINGTON, VIRGINIA 22202

RECEIVED

DEC 14 2001

TECH CENTER 1600/2900

Enclosed for filing in the application referenced above are the following:

- ☒ Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- ☒ Second Preliminary Amendment and Marked-Up Version of Specification
- ☒ Sequence Listing
  - ☒ Computer Readable Copy
  - ☒ Paper Copy (identical to computer copy), 19 pages
  - ☒ Statement in compliance with 37 C.F.R. § 1.821 verifying identity of computer-readable and paper copies
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/847,172	05/01/2001	Gregory G. Burrows	899-58137

24197  
KLARQUIST SPARKMAN, LLP  
121 SW SALMON STREET  
SUITE 1600  
PORTLAND, OR 97204

**RECEIVED**

DEC 14 2001

TECH CENTER 1600/2900

CONFIRMATION NO. 5303

FORMALITIES LETTER



\*OC000000006881083\*

Date Mailed: 10/10/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE